Cargando…
Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment
Aiming to improve the treatment outcomes of current daily tuberculosis (TB) chemotherapy over several months, we investigated whether nanoencapsulation of existing drugs would allow decreasing the treatment frequency to weekly, thereby ultimately improving patient compliance. Nanoencapsulation of th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724112/ https://www.ncbi.nlm.nih.gov/pubmed/31443150 http://dx.doi.org/10.3390/nano9081167 |
_version_ | 1783448928748830720 |
---|---|
author | Kalombo, Lonji Lemmer, Yolandy Semete-Makokotlela, Boitumelo Ramalapa, Bathabile Nkuna, Patric Booysen, Laetitia L.L.I.J. Naidoo, Saloshnee Hayeshi, Rose Verschoor, Jan A. Swai, Hulda S. |
author_facet | Kalombo, Lonji Lemmer, Yolandy Semete-Makokotlela, Boitumelo Ramalapa, Bathabile Nkuna, Patric Booysen, Laetitia L.L.I.J. Naidoo, Saloshnee Hayeshi, Rose Verschoor, Jan A. Swai, Hulda S. |
author_sort | Kalombo, Lonji |
collection | PubMed |
description | Aiming to improve the treatment outcomes of current daily tuberculosis (TB) chemotherapy over several months, we investigated whether nanoencapsulation of existing drugs would allow decreasing the treatment frequency to weekly, thereby ultimately improving patient compliance. Nanoencapsulation of three first-line anti-TB drugs was achieved by a unique, scalable spray-drying technology forming free-flowing powders in the nanometer range with encapsulation efficiencies of 82, 75, and 62% respectively for rifampicin, pyrazinamide, and isoniazid. In a pre-clinical study on TB infected mice, we demonstrate that the encapsulated drugs, administered once weekly for nine weeks, showed comparable efficacy to daily treatment with free drugs over the same experimental period. Both treatment approaches had equivalent outcomes for resolution of inflammation associated with the infection of lungs and spleens. These results demonstrate how scalable technology could be used to manufacture nanoencapsulated drugs. The formulations may be used to reduce the oral dose frequency from daily to once weekly in order to treat uncomplicated TB. |
format | Online Article Text |
id | pubmed-6724112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67241122019-09-10 Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment Kalombo, Lonji Lemmer, Yolandy Semete-Makokotlela, Boitumelo Ramalapa, Bathabile Nkuna, Patric Booysen, Laetitia L.L.I.J. Naidoo, Saloshnee Hayeshi, Rose Verschoor, Jan A. Swai, Hulda S. Nanomaterials (Basel) Article Aiming to improve the treatment outcomes of current daily tuberculosis (TB) chemotherapy over several months, we investigated whether nanoencapsulation of existing drugs would allow decreasing the treatment frequency to weekly, thereby ultimately improving patient compliance. Nanoencapsulation of three first-line anti-TB drugs was achieved by a unique, scalable spray-drying technology forming free-flowing powders in the nanometer range with encapsulation efficiencies of 82, 75, and 62% respectively for rifampicin, pyrazinamide, and isoniazid. In a pre-clinical study on TB infected mice, we demonstrate that the encapsulated drugs, administered once weekly for nine weeks, showed comparable efficacy to daily treatment with free drugs over the same experimental period. Both treatment approaches had equivalent outcomes for resolution of inflammation associated with the infection of lungs and spleens. These results demonstrate how scalable technology could be used to manufacture nanoencapsulated drugs. The formulations may be used to reduce the oral dose frequency from daily to once weekly in order to treat uncomplicated TB. MDPI 2019-08-15 /pmc/articles/PMC6724112/ /pubmed/31443150 http://dx.doi.org/10.3390/nano9081167 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kalombo, Lonji Lemmer, Yolandy Semete-Makokotlela, Boitumelo Ramalapa, Bathabile Nkuna, Patric Booysen, Laetitia L.L.I.J. Naidoo, Saloshnee Hayeshi, Rose Verschoor, Jan A. Swai, Hulda S. Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment |
title | Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment |
title_full | Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment |
title_fullStr | Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment |
title_full_unstemmed | Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment |
title_short | Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment |
title_sort | spray-dried, nanoencapsulated, multi-drug anti-tuberculosis therapy aimed at once weekly administration for the duration of treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724112/ https://www.ncbi.nlm.nih.gov/pubmed/31443150 http://dx.doi.org/10.3390/nano9081167 |
work_keys_str_mv | AT kalombolonji spraydriednanoencapsulatedmultidrugantituberculosistherapyaimedatonceweeklyadministrationforthedurationoftreatment AT lemmeryolandy spraydriednanoencapsulatedmultidrugantituberculosistherapyaimedatonceweeklyadministrationforthedurationoftreatment AT semetemakokotlelaboitumelo spraydriednanoencapsulatedmultidrugantituberculosistherapyaimedatonceweeklyadministrationforthedurationoftreatment AT ramalapabathabile spraydriednanoencapsulatedmultidrugantituberculosistherapyaimedatonceweeklyadministrationforthedurationoftreatment AT nkunapatric spraydriednanoencapsulatedmultidrugantituberculosistherapyaimedatonceweeklyadministrationforthedurationoftreatment AT booysenlaetitiallij spraydriednanoencapsulatedmultidrugantituberculosistherapyaimedatonceweeklyadministrationforthedurationoftreatment AT naidoosaloshnee spraydriednanoencapsulatedmultidrugantituberculosistherapyaimedatonceweeklyadministrationforthedurationoftreatment AT hayeshirose spraydriednanoencapsulatedmultidrugantituberculosistherapyaimedatonceweeklyadministrationforthedurationoftreatment AT verschoorjana spraydriednanoencapsulatedmultidrugantituberculosistherapyaimedatonceweeklyadministrationforthedurationoftreatment AT swaihuldas spraydriednanoencapsulatedmultidrugantituberculosistherapyaimedatonceweeklyadministrationforthedurationoftreatment |